Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Debt: 2023-2024

Historic Total Debt for Spyre Therapeutics (SYRE) over the last 2 years, with Dec 2024 value amounting to $25.1 million.

  • Spyre Therapeutics' Total Debt fell 55.46% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 55.46%. This contributed to the annual value of $25.1 million for FY2024, which is 1704.32% up from last year.
  • Spyre Therapeutics' Total Debt amounted to $25.1 million in FY2024, which was up 1,704.32% from $1.4 million recorded in FY2023.
  • Over the past 5 years, Spyre Therapeutics' Total Debt peaked at $25.1 million during FY2024, and registered a low of $1.4 million during FY2023.
  • For the 2-year period, Spyre Therapeutics' Total Debt averaged around $13.2 million, with its median value being $13.2 million (2023).
  • Data for Spyre Therapeutics' Total Debt shows a peak YoY skyrocketed of 1,704.32% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Spyre Therapeutics' Total Debt stood at $1.4 million in 2023, then spiked by 1,704.32% to $25.1 million in 2024.